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ABSTRACT
Most multidrug-resistant (MDR) Mycobacterium tuberculosis isolates in Russia belong to the Beijing or
Latino-American and Mediterranean (LAM) spoligotype families. The objective of this study was to
investigate possible associations between genotype and the frequencies of mutations that confer drug
resistance in a population that has two large families of circulating strains. Spoligotyping, IS6110
restriction fragment length polymorphism typing, and sequencing of the katG and rpoB genes, were
performed for 217 consecutive MDR M. tuberculosis isolates from patients. The rpsL and rrs genes were
also sequenced for selected streptomycin-resistant isolates. Of the 217 MDR isolates, 99 (46%) belonged
to the LAM family, 92 (42%) to the Beijing family, 21 (10%) to the Haarlem family and four (2%) to the T
family. There was one unique spoligotype. Mutations in the katG gene were identiﬁed in 207 (95%)
isolates, all of which had mutations in codon 315. Mutations in the rpoB gene were identiﬁed in 200
(92%) isolates; 75% of LAM isolates carried a mutation in codon 516, whereas 71% of Beijing isolates
carried a mutation in codon 531. In the 33 isolates resistant to streptomycin 50 mg ⁄L, the 43AGG rpsL
mutation was found in 27% of Haarlem, 75% of Beijing and 0% of LAM isolates, and rrsmutations were
found in 17% (516C ﬁ T) of Beijing and 100% (513A ﬁ C) of LAM isolates. Overall, there appeared to
be a correlation between the genotype and speciﬁc mutations conferring resistance to rifampicin or
streptomycin in the Beijing and LAM families. The biological implications of this correlation remain to
be explored.
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INTRODUCTION
Tuberculosis (TB) is an urgent public health
problem in both industrialised and developing
countries. Efforts to control TB have recently been
complicated by the worldwide spread of multi-
drug-resistant (MDR; resistant to at least isoniazid
and rifampicin) strains of Mycobacterium tubercu-
losis [1]. In several regions of the world, the
spread of MDR TB has been associated with the
expansion of strains belonging to the Beijing
family [2]. Drug resistance results from the
accumulation of chromosomal mutations, in part
because tubercle bacilli have no known efﬁcient
mechanism for horizontal gene transfer [3].
Despite the need for several independent muta-
tions, resistance to multiple drugs is not uncom-
mon, as successive rounds of inadequate or
inappropriate therapy, or incomplete compliance,
can lead to the stepwise accumulation of drug
resistance mutations [1]. In the mycobacteria,
rifampicin resistance is associated with changes
in the rpoB gene, and isoniazid resistance is
associated primarily with changes in the katG,
inhA or aphC genes [4–7].
Genotyping of M. tuberculosis isolates has pro-
ven to be a powerful approach for investigating
transmission dynamics, circulating strains, and
the natural history of TB. The commonly used
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genotyping methods are spoligotyping, IS6110
restriction fragment length polymorphism (RFLP)
typing, and mycobacterial interspersed repetitive
unit typing [8–10]. Families of M. tuberculosis
isolates are deﬁned on the basis of shared spolig-
otypes or closely related IS6110 RFLP patterns.
The distribution of M. tuberculosis genotype fam-
ilies varies greatly by region [11,12]. In Russia, the
majority ofM. tuberculosis isolates belong to either
the Beijing or Latino-American and Mediterra-
nean (LAM) families [13–17].
Because genotyping techniques measure varia-
tions in the M. tuberculosis genome unrelated to
the acquisition of drug resistance, it was some-
what surprising to ﬁnd that certain mutations
appear to predominate in drug-resistant members
of some families. For example, the katG 315
mutation appears to predominate in isoniazid-
resistant isolates of the Beijing family [7,17,18].
The objective of the present study was to take
advantage of the presence of two large families of
strains in Russia to investigate correlations be-
tween speciﬁc drug resistance mutations and the
genotype of MDR strains of M. tuberculosis.
MATERIALS AND METHODS
Patients
In total, 312 consecutive M. tuberculosis isolates resistant to at
least one anti-TB drug were obtained from 312 pulmonary
TB patients in two neighbouring regions, Tula and Serpuk-
hov District of Moscow, between 1998 and 2001. Of these
patients, 241 (77.2%) were chronic cases, 285 (91.3%) were
male, and none was infected with human immunodeﬁciency
virus; the mean age was 43 years. Resistance to both
isoniazid and rifampicin was detected in isolates from 217
patients (of whom 93.1% were chronic cases and 92.2% were
male). Only the 217 MDR isolates were included in this
study.
Drug susceptibility testing
Isolates were tested for susceptibility to isoniazid, streptomy-
cin, rifampicin, kanamycin and ethambutol, using the absolute
concentration method on Loewenstein–Jensen medium [19].
The concentrations of the drugs used in the medium were: for
isoniazid, 1, 5 and 25 mg ⁄L; for streptomycin, 5, 10 and
50 mg ⁄L; for rifampicin, 20 and 50 mg ⁄L; for kanamycin, 30
and 50 mg ⁄L; and for ethambutol, 2 and 5 mg ⁄L. Isolates that
grew on the lowest concentration of the drug tested were
considered to be resistant to that drug.
Genotyping
Spoligotyping was performed as described previously [8],
using membranes made at the CDC. IS6110 RFLP typing of
M. tuberculosis isolates was carried out as described previously
[9]. IS6110 RFLP images on ﬁlms were scanned (200 dpi, 256
grayscales) and processed with GelCompar II v.2.5 (Applied
Maths, Sint-Martens-Latem, Belgium) software. Sets of restric-
tion fragments were considered as vectors in multidimensional
Euclid space [15] and processed with the unweighted pair-
group method using arithmetic averages (Jaccard’s similarity
coefﬁcient, tolerance 1.0%, optimisation 0.7%).
DNA sequencing
DNA samples were prepared as described previously [9].
Primers for PCR ampliﬁcation and sequencing are listed in
Table 1. The primers were selected to amplify and sequence
the rifampicin resistance-determining region (RRDR) of the
rpoB gene (bases 1366–1772; Escherichia coli numbering system),
697 bp of the katG gene, including the region around codon
315 (bases 872–1568), the entire katG gene (bases )23 to +2232),
248 bp and 283 bp of the inhA (bases )168 to +79) and ahpC
(bases )182 to +100) regulatory regions, 373 bp of the rpsL
gene, including the region around codon 43 (bases 12–384),
and 553 bp of the rrs gene, including the region around
nucleotide 530 (bases 427–980).
The ampliﬁcation mixture consisted of PCR buffer contain-
ing 2.5 mM MgCl2 (Fermentas, Vilnius, Lithuania), DNA
0.2 ng ⁄ lL, 0.15 mM each dNTP (Fermentas), 0.4 lM forward
and reverse primers (Syntol, Moscow, Russia), and 0.05 U ⁄ lL
Taq DNA polymerase (Fermentas). Thermocycling conditions
comprised 95C for 4 min, 25 cycles of 30 s at 95C, 30 s at
Table 1. Primers used for PCR
ampliﬁcation and sequencing
Gene Forward primer, 5¢)3¢ Reverse primer, 5¢)3¢
katG fragment
(217 isolates)
















Ampliﬁcation and sequencing Ampliﬁcation
CCGCAACGTCGACTGGCTCA CGATGAGAGCGGTGAGCTGG
rpsL Ampliﬁcation Ampliﬁcation and sequencing
CCAGCAGCTGGTCCGCAAGG TGCGTGGCATCAGCCCTTCTC
16S rRNA Ampliﬁcation and sequencing Ampliﬁcation and sequencing
TAAACCTCTTTCACCATCGACGA CCAGGTAAGGTTCTTCGCGTTG
rpoB Ampliﬁcation and sequencing Ampliﬁcation and sequencing
GTCGGCGAGCTGATCCAAAAC GGTACGGCGTTTCGATGAACC
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57C and 60 s at 72C, followed by 30 s at 57C, 5 min at 72C,
and cooling to 10C. Amplicons were puriﬁed by electrophor-
esis on agarose 1% w ⁄v gels, followed by recovery with a
DNA extraction kit (Fermentas). Sequencing was performed
using the Thermo Sequenase Radiolabelled Terminator Cycle
Sequencing kit (Fermentas) according to Sanger et al. [20], with
a thermocycling proﬁle of 94C for 3 min, 25 cycles of 30 s at
94C, 30 s at 57C and 60 s at 72C, followed by 30 s at 57C,
5 min at 72C, and cooling to 10C. Sequences were compared
to those of the wild-type (WT) genes of strain H37Rv (http://
www.ncbi.nlm.nih.gov).
Statistical methods
CIs (95%) and the probability, p, that a difference between
mean values is casual, were estimated using binomial distri-
bution.
RESULTS
The spoligotyping analysis identiﬁed four (1.8%)
T family, 21 (9.7%) Haarlem family, 92 (42.4%)
Beijing family and 99 (45.6%) LAM family iso-
lates. The spoligotype of one isolate did not
belong to a known family. IS6110 RFLP typing
revealed 94 (43.3%) different strains with unique
proﬁles, comprising 33 LAM, 37 Beijing, 19
Haarlem and four T family strains. The results
of IS6110 RFLP typing were used to select isolates
for sequencing (rpsL, rrs, inhA and ahpC genes) in
order to avoid sequencing multiple isolates of the
same strain.
In addition to being resistant to isoniazid and
rifampicin, all 217 MDR isolates were resistant to
streptomycin, 150 (69%) were resistant to kana-
mycin, and 178 (82%) were resistant to ethambu-
tol. The frequency of kanamycin-resistant isolates
was greater in the LAM family than in the Beijing
and Haarlem families (83%, 60% and 38%,
respectively; p <0.0003). There was no signiﬁcant
difference in the frequency of ethambutol-resis-
tant isolates among the LAM, Beijing, Haarlem
and T families.
Mutations in the katG gene were identiﬁed in
207 (95.4%) of the 217 MDR isolates, including
99% of the MDR isolates in the LAM family
(codon 315ACC, n = 97; 315AGA, n = 1), 57% of
the MDR isolates in the Haarlem family (315ACC,
n = 12), and all of the MDR isolates in the Beijing
(315ACC, n = 91; 315AGA and 335GTC, n = 1)
and T families (315ACC, n = 4). All Beijing family
isolates also carried the codon 463CTG poly-
morphism. However, this polymorphism is not
associated with isoniazid resistance [21], but is
one of the genetic polymorphisms used to identify
the principal genotypic groups of M. tuberculosis
isolates [3]. The frequency of isoniazid-resistant
isolates with a WT katG gene in the region
sequenced (697 bp) was greater in the Haarlem
family than in the LAM and Beijing families (43%,
1%, and 0%, respectively; p <0.001). The isonia-
zid-resistant isolate with the unclassiﬁed spoligo-
type had mutations in codons 315ACC and
463CTG of the katG gene. The frequency of
isoniazid-resistant isolates that carried a mutation
in katG codon 315 and were resistant to the high
(25 mg ⁄L) concentration of isoniazid was greater
in the LAM family (n = 47, 48%) than in the
Beijing (n = 8, 8.7%; p <0.001) and Haarlem
(n = 2, 17%; p <0.04) families (Fig. 1).
In order to investigate the high isoniazid
resistance of some isolates carrying the codon
315 katG mutation, the regulatory regions of two
other genes (inhA and ahpC) known to inﬂuence
isoniazid resistance were sequenced in isolates
that carried a codon 315 mutation and did not
belong to the same IS6110 RFLP cluster. None of
the isolates of any family had more than one
mutation in the regulatory sequences of the inhA
and ahpC genes. A mutation in the regulatory
region of the ahpC gene ()30C ﬁ T) was detected
in one of the eight Beijing family isolates resistant
to isoniazid 25 mg ⁄L. Mutations in the regulatory
region of the inhA gene ()15C ﬁ T) were detected
in three of the eight Beijing family isolates
resistant to isoniazid 25 mg ⁄L, in two of the nine
Beijing family isolates resistant to isoniazid
1 mg ⁄L, in all 14 LAM family isolates resistant
to isoniazid 25 mg ⁄L, in nine of the ten LAM
family isolates resistant to isoniazid 1 mg ⁄L, in
neither of two Haarlem family isolates resistant to
isoniazid 25 mg ⁄L, and in two of four Haarlem
family isolates resistant to isoniazid 1 mg ⁄L.














Fig. 1. Level of resistance to isoniazid in isoniazid-resist-
ant Mycobacterium tuberculosis isolates belonging to differ-
ent families.
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mutation in isolates resistant to isoniazid 25 mg ⁄L
and those resistant to isoniazid 1 mg ⁄L in any
family was not signiﬁcant (p ‡0.4).
In order to determine the molecular basis for
resistance to the high concentration of streptomy-
cin, the rpsL and rrs (16S rRNA) genes were
sequenced in selected isolates that did not belong
to the same IS6110 RFLP cluster and had resist-
ance to streptomycin 50 mg ⁄L. The 513A ﬁ C
mutation in the rrs gene was detected in all ten
LAM family isolates tested. The codon 43AAG
ﬁ AGG mutation was detected in the rpsL gene
of three (27%) of 11 Haarlem family isolates
tested, and in nine (75%) of 12 Beijing family
isolates tested, while the 516C ﬁ T mutation in
the rrs gene was detected in two (17%) Beijing
family isolates (Fig. 2). The frequency (73%) of
streptomycin-resistant (50 mg ⁄L) isolates with
mutations in neither the rpsL nor the rrs genes in
the Haarlem family was greater than that in the
LAM (0%, p <0.001) or Beijing (8%, p <0.001)
families.
The rpsL and rrs genes were also sequenced in
ﬁve Beijing family isolates showing resistance to
streptomycin 10 mg ⁄L and susceptibility to strep-
tomycin 50 mg ⁄L; the 43AAG ﬁ AGG mutation
in the rpsL gene was detected in one (20%) isolate,
and the 516C ﬁ T mutation in the rrs gene was
detected in four (80%) isolates. The frequency of
the 43AAG ﬁ AGG mutation in the Beijing fam-
ily isolates with resistance to streptomycin
50 mg ⁄L was greater than that in isolates with
resistance only to streptomycin 10 mg ⁄L (75% vs.
20%; p 0.06).
Mutations in the RRDR of the rpoB gene were
identiﬁed in 200 (92%) of the 217 MDR isolates.
The most frequent mutations were substitutions
in codons 516, 526 or 531 of the rpoB gene, which
were found in 194 (89%) of the 217 isolates. The
mutations in the rpoB gene of the 92 MDR
isolates of the Beijing family were 511CCG
(n = 2), 513CCA (n = 1), 514–515 deletion
CAT (n = 1), 516GTC (n = 3), 516TAC (n = 2),
522TTG (n = 1), 525ACG + 526TAC + 527CAG
(n = 1), 526CGC (n = 1), 526CTC (n = 1),
526GAC (n = 6), 526TAC (n = 5), 531TGG
(n = 1), 531TTG (n = 64) and 533CCG (n = 1);
two isolates had no mutations in the RRDR of the
rpoB gene. Mutations in codon 531 of the rpoB
gene were detected in 65 (71%) of 92 MDR
isolates of the Beijing family.
The rpoB mutations in the 99 MDR isolates of
the LAM family were 516GTC (n = 73), 516TAC
(n = 1), 522CAG (n = 1), 526CTC (n = 1), 526GAC
(n = 11), 526TAC (n = 1) and 531TTG (n = 7); four
isolates had no mutations in the RRDR of the rpoB
gene. Mutations in codon 516 of the rpoB gene
were detected in 74 of the 99 MDR isolates of the
LAM family.
The rpoB mutations in the 21 MDR isolates of
the Haarlem family were 516GTC (n = 1), 516TAC
(n = 1), 526GAC (n = 2), 526TAC (n = 2), 531TTG
(n = 4) and 533CCG (n = 1); ten isolates had no
mutations in the RRDR of the rpoB gene. The
frequency (48%) of MDR isolates in the Haarlem
family with a WT rpoB gene was greater than that
in the LAM (4%, p <0.001) or Beijing (2%,
p <0.001) families (Fig. 3).
The rpoB mutations in the four MDR isolates of
the T family were 516GTC (n = 2), 526GAC
(n = 1) and 526TAC (n = 1). The MDR isolate
with the unclassiﬁed spoligotype had a WT rpoB
gene.
Isolates in the same IS6110 RFLP cluster often
had different mutations in the rpoB gene. For
example, the correlation coefﬁcient between the
Fig. 2. Mutations in the rpsL and 16S rRNA genes of
streptomycin-resistant (50 mg ⁄L) Mycobacterium tuberculo-
sis isolates belonging to different families (WT, wild-type).
Fig. 3. Mutations in the rpoB gene in rifampicin-resistant
Mycobacterium tuberculosis isolates belonging to different
families (WT, wild-type).
Lipin et al. TB drug resistance mutations and spoligotypes 623
 2007 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 13, 620–626
presence of the mutation 531TTG and the afﬁli-
ation of an isolate with the largest IS6110 RFLP
cluster (n = 35) of the Beijing family was 0.032. A
correlation between the position of a mutation in
the rpoB gene and the afﬁliation of an isolate with
a particular IS6110 RFLP cluster was detected for
only one cluster containing 43 isolates of the LAM
family (p 0.51), but afﬁliation of an isolate with
this cluster and the level of rifampicin resistance
were not correlated (p 0.02).
Of the 217 MDR isolates, ten carried no
mutations in the sequenced region of the katG
gene, 17 carried no mutations in the RRDR of
the rpoB gene, and eight carried no mutations in
the sequenced regions of both the katG and rpoB
genes. One of these eight isolates belonged to
the LAM family and produced 20 colonies on
Loewenstein–Jensen medium containing rif-
ampicin 20 mg ⁄L, which was the minimum
number required to consider an isolate as
rifampicin-resistant; the other seven isolates
belonged to the Haarlem family. Regulatory
regions of the inhA and ahpC genes were
sequenced for these eight MDR isolates, and
all eight had a WT regulatory sequence for the
inhA gene. Three isolates of the Haarlem family
had either the )6G ﬁ A, )10C ﬁ T or
)32G ﬁ A mutations in the regulatory sequence
of the ahpC gene. As mutations in this regula-
tory region often coincide with deletions in the
katG gene, the entire katG sequence of these
isolates was determined, revealing that each
isolate had a WT katG sequence.
DISCUSSION
Beijing family strains of M. tuberculosis are pre-
valent in many regions of the world and are often
associated with drug resistance [2,12]. According
to published data [14–16], LAM family strains are
also prevalent in some regions of Russia, and are
also associated with drug resistance. It is inter-
esting that members of two of the principal
genetic groups (Beijing family, group 1; LAM
family, group 2 [3]) of M. tuberculosis are highly
prevalent in TB patients in the same regions of
Russia. It has been suggested that the prevalence
of Beijing family strains is a result of the ability of
these strains to overcome the protective effects of
vaccination of the population with bacille
Calmette-Gue´rin [22]. A similar explanation may
apply to the LAM family strains, which occur at a
high frequency in the Russian population, which
has a high rate of bacille Calmette-Gue´rin vaccin-
ation.
As has been observed previously for isolates
in Russia, mutations in codon 315 of the katG gene
are found in the vast majority of isoniazid-resist-
ant isolates [16,18]. However, the frequency of
codon 315 mutations in isoniazid-resistant isolates
in other populations has been reported to range
from 35% to 97% [7]. Mutations in codon 315 do
not signiﬁcantly decrease the peroxidase activity
of the katG gene product, but do decrease its ability
to activate isoniazid [23]. These features allow the
mutants to maintain the peroxidase activity
required for virulence, and to resist killing by
isoniazid. Such isolates often display resistance to
only lower levels of isoniazid, and resistance to
higher levels appears to correlate with loss of
catalase activity or acquisition of mutations in
multiple genes implicated in isoniazid resistance,
e.g., inhA or ahpC [4,5]. However, in the present
study, resistance of the isolates carrying the codon
315 mutations to a high concentration of isoniazid
(25 mg ⁄L) did not correlate with the presence of
mutations in either the inhA or ahpC genes.
The striking difference between the frequencies
of various mutations in the rpsL and rrs genes of
streptomycin-resistant isolates (Fig. 2) was unex-
pected. As only isolates with different IS6110
RFLP proﬁles were selected for PCR sequencing,
this dissimilarity cannot be explained by the
existence of multiple isolates of the same strain.
High-level streptomycin resistance has been cor-
related previously [4] with acquisition of the rpsL
codon 43AAG ﬁ AGG mutation, while low-level
streptomycin resistance was correlated with chan-
ges in the rrs gene, as was observed in the present
study for the Beijing family isolates. The correla-
tion of the rrs 513A ﬁ C mutation with high-level
streptomycin resistance in the LAM family iso-
lates is unusual. The molecular basis for this
difference is unknown.
The frequencies of mutations in rpoB codons
516 (5.4%), 526 (15%) and 531 (71%) of the Beijing
family isolates are similar to those reported for
isolates in the north-west region of Russia [13]
and the Archangel region [17]. The mutation
531TTG in rpoB is the most commonly observed
mutation in rifampicin-resistant isolates in many
parts of the world, e.g., in Brazil (54%) [24], the
USA (35%) [25], India (38.7%) [26], Germany
(65%) [27] and Australia (52%) [28]. The
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predominance of mutations in rpoB codon 531 of
the rifampicin-resistant isolates belonging to the
Beijing family is in good agreement with frequen-
cies of mutations in codons of the rpoB gene and
rates of growth of spontaneous rifampicin-resist-
ant mutants of M. tuberculosis strain H37Rv [29],
andMycobacterium leprae,Mycobacterium africanum
and Mycobacterium avium strains [30]. Thus, the
predominance of mutations in rpoB codon 516 of
the rifampicin-resistant isolates of the LAM fam-
ily is unusual. Interestingly, mutations in codon
516 of the rpoB gene confer a low level of cross-
resistance to rifabutin and KRM-1648 [30,31].
As different mutations in the rpoB gene were
detected in the same IS6110 RFLP cluster, the rpoB
gene mutations appear to have been acquired
independently in most isolates during the course
of chemotherapy. As such, differences in the
frequencies of mutations in the 516, 526 and 531
codons of the rpoB gene among isolates of the
Beijing, Haarlem and LAM families may primar-
ily reﬂect differences in mutational frequencies or
the relative ﬁtness of the mutations in the strain
families, as opposed to a possible sampling bias
caused by extensive transmission of individual
MDR strains.
The ﬁnding that eight (3.7%) of the 217 MDR
isolates did not contain mutations in the se-
quenced regions of the katG and rpoB genes was
initially surprising. Given the observed frequen-
cies of mutations in the sequenced regions of the
katG gene in isoniazid-resistant isolates (95%) and
in the sequenced regions of the rpoB gene of
rifampicin-resistant isolates (92%), fewer than
two such isolates would be expected in a sample
of 217 isolates if acquisition of isoniazid and
rifampicin resistances was independent. How-
ever, seven of these eight isolates were members
of the Haarlem family and, in this family, only
57% (12 of 21) of isoniazid-resistant isolates had
mutations in the sequenced regions of the katG
gene, and 52% (11 of 21) of rifampicin-resistant
isolates had mutations in the RRDR of the rpoB
gene. Thus, the number of observed isolates
without mutations is consistent with the inde-
pendent frequencies of mutations in the individ-
ual genes in isolates of the Haarlem family. The
low frequency of mutations revealed in the katG
and rpoB genes of MDR Haarlem isolates does not
correspond with data concerning 21 MDR Haar-
lem isolates in Tunisia [32]. However, that study
involved a clonal outbreak of an MDR Haarlem
strain, conﬁrmed by IS6110 RFLP typing [32],
whereas the present study analysed the data for
19 isolates with different IS6110 RFLP proﬁles.
Overall, the data indicate that the frequencies
of individual mutations in the genes associated
with rifampicin and streptomycin resistance vary
dramatically among isolates belonging to differ-
ent genotype families. Such variation may inﬂu-
ence the performance of molecular diagnostic
tests designed to detect mutations associated with
drug resistance in M. tuberculosis isolates. This
emphasises the importance of validating the
performance of a diagnostic test in the population
being tested. The biological signiﬁcance of the
predominance of certain mutations in particular
genotype families remains to be determined.
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